4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)
$9.81 -0.03 (-0.3049%)
Analysed 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) News Sources
electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?
10-04-2026
yahoo.com
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
18-03-2026
yahoo.com
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
18-03-2026
yahoo.com
4DMT to Participate in Upcoming Investor Meetings
16-03-2026
yahoo.com
4D Molecular Therapeutics Highlights 4D-150 Phase III Momentum, DME Plans, Cash Runway at Leerink Conference
16-03-2026
marketbeat.com
4D Molecular Therapeutics Maps Phase 3 4D-150 Timeline, DME Expansion in Barclays Conference Talk
16-03-2026
marketbeat.com
Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street?
28-02-2026
yahoo.com
4DMT to Participate in Upcoming Investor Conferences
19-02-2026
yahoo.com
4DMT Announces New Employment Inducement Grants
13-02-2026
yahoo.com
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
09-02-2026
yahoo.com
What is the current price of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)?
The current price of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) is $9.81.
4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) absolute price change since previous trading day?
The absolute price change of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) since the previous trading day is $-0.03.
4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) percentage price change since previous trading day?
The percentage price change of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) since the previous trading day is -0.3049%.
What is the most recent average sentiment score for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)?
The most recent average sentiment score for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) is 83 out of 100.
What is the most recent average sentiment for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)?
The most recent sentiment for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) is .
SEC-8K** Filing Available For 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.